Celldex second quarter net loss increases to $10.

G&A expenditure reduced by $0.8 million to $4.6 million in 2011 as compared to G&A expense of $5.4 million in the first six months of 2010, primarily due to reduced stock-based compensation, patent and other professional services expenses incurred in 2011. The $1.june 30 2 million reduce in amortization expense for the six months ended, 2011 was primarily because of the amortization this year 2010 of intangible resources acquired regarding the the CuraGen acquisition. The $3.3 million decrease in purchase, other income and interest expense, net in 2011 is primarily because of other income of $3.0 million recorded for the TopoTarget sublicense income payment received this year 2010. As of June 30, 2011, Celldex had approximately 44.1 million shares outstanding.. Celldex second quarter net loss increases to $10.2 million Celldex Therapeutics, Inc.This form of skin cancer may be the least deadly and with proper treatment can be totally eliminated with not so much as a single scar squamous cell remaining. Currently, surgical excision is the most common type of treatment for skin cancers, but brand-new discoveries using 100 percent natural ingredients are taking over now. The application of crocodile essential oil to the surface of the skin has had an extraordinary effect on patients worldwide. Most say that within four weeks of application, the cancerous skin simply peels off without leaving a trace. Prevention is better than cure use a sunscreen Sunscreen is a straightforward, easy, and convenient artificial defense against epidermis cancer.